Registered title, quoted from ClinicalTrials.gov
A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by National Cancer Center / Cancer Hospital, CAMS; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07083375, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically or cytologically confirmed, treatment-naïve extensive-stage small cell lung cancer (ES-SCLC).
Inclusion criterion 5
ECOG performance status of 0 or 1.
Inclusion criterion 4
Absolute neutrophil count ≥1.5 × 10⁹/L
Inclusion criterion 10
Platelets ≥100 × 10⁹/L
Inclusion criterion 11
Hemoglobin ≥90 g/L (without transfusion in prior 14 days)
Inclusion criterion 12
Serum creatinine ≤1× ULN or creatinine clearance >50 mL/min (Cockcroft-Gault)
Inclusion criterion 13
AST and ALT ≤2.5× ULN (≤5× ULN with liver metastases)
Inclusion criterion 14
Total bilirubin ≤1.5× ULN (except Gilbert's syndrome <51.3 µmol/L)
Inclusion criterion 15
At least one measurable lesion per RECIST v1.1.
Inclusion criterion 7
Positive for HIV antibodies, active HBV (HBsAg+ with HBV DNA >10³ copies/mL), or active HCV infection (HCV-Ab+ with detectable RNA).
Exclusion criterion 9
History of other malignancies within 2 years, except for cured non-melanoma skin cancers or certain in situ carcinomas.
Exclusion criterion 13
Pregnant or breastfeeding females.
Exclusion criterion 7
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07083375, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
Participants must meet all of the following criteria to be eligible for the study:
- Signed written informed consent and willingness to comply with study procedures.
- Age ≥18 years.
- Estimated life expectancy ≥3 months.
- ECOG performance status of 0 or 1.
- Histologically or cytologically confirmed, treatment-naïve extensive-stage small cell lung cancer (ES-SCLC).
- Willing to provide archived or fresh tumor tissue samples. If unavailable, enrollment may proceed per investigator assessment.
- At least one measurable lesion per RECIST v1.1.
- Fully understands and voluntarily participates in the study.
- Adequate organ function as defined below:
- Absolute neutrophil count ≥1.5 × 10⁹/L
- Platelets ≥100 × 10⁹/L
- Hemoglobin ≥90 g/L (without transfusion in prior 14 days)
- Serum creatinine ≤1× ULN or creatinine clearance >50 mL/min (Cockcroft-Gault)
- AST and ALT ≤2.5× ULN (≤5× ULN with liver metastases)
- Total bilirubin ≤1.5× ULN (except Gilbert's syndrome <51.3 µmol/L)
- TSH, FT3, FT4 within ±10% of normal limits
Exclusion Criteria:
- Prior chemotherapy, immunotherapy, targeted therapy, or radiotherapy.
- Histologic or cytologic evidence of non-small cell or mixed small cell/non-small cell carcinoma.
- Symptomatic brain metastases or leptomeningeal disease.
- Active or suspected autoimmune disease, except for stable vitiligo, type 1 diabetes, hypothyroidism requiring only hormone replacement, or conditions not expected to recur.
- Evidence or history of active pulmonary tuberculosis (TB), including treated TB within the past year.
- Concomitant condition requiring systemic corticosteroids or other immunosuppressive therapy.
- Pregnant or breastfeeding females.
- Symptomatic interstitial lung disease or suspected drug-related pneumonitis.
- Positive for HIV antibodies, active HBV (HBsAg+ with HBV DNA >10³ copies/mL), or active HCV infection (HCV-Ab+ with detectable RNA).
- History of significant neurological or psychiatric disorders (e.g., dementia, depression, epilepsy, bipolar disorder).
- Participation in another investigational drug study within 4 weeks prior to randomization.
- Use of anti-tumor traditional Chinese medicine within 2 weeks prior to first study dose.
- History of other malignancies within 2 years, except for cured non-melanoma skin cancers or certain in situ carcinomas.
- Clinically significant cardiovascular or cerebrovascular disease (e.g., NYHA class ≥2 heart failure, recent myocardial infarction or stroke within 6 months).
- History of thromboembolic events (e.g., DVT, PE, arterial thrombosis) within 6 months, except catheter-related thrombosis.
- Live vaccination within 28 days before randomization or planned during the study.
- Major surgery or significant trauma within 4 weeks prior to treatment initiation.
- Conditions affecting drug absorption (e.g., severe vomiting, GI obstruction, active GI bleeding or perforation).
- Active, uncontrolled bacterial, viral, or fungal infections despite appropriate treatment.
- Known hypersensitivity to any study drug or excipients.
- Any other condition deemed unsuitable by the investigator due to safety or compliance concerns.
Quoted from ClinicalTrials.gov, NCT07083375, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07083375, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.